Form 4: Tyra Biosciences Director Gilla Kaplan Acquires Stock Options

Director Gilla Kaplan acquired 18,600 stock options in Tyra Biosciences, Inc. on May 29, 2024, according to a Form 4 filing.

Summary

• Gilla Kaplan, a director of Tyra Biosciences, Inc., was granted 18,600 stock options on May 29, 2024.
• The exercise price of these options is $15.94.
• The options were granted pursuant to the Issuer's Non-Employee Director Compensation Program.
• The options vest monthly, with 1/12th of the total shares vesting each month following the grant date.
• Any remaining unvested portion of the option will vest on the date of the next occurring annual meeting of the Issuer's stockholders if it occurs before the first anniversary of the grant date, subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices, aligning director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The options vest monthly following May 29, 2024, with any remaining unvested portion vesting at the next annual meeting if it occurs before the first anniversary of the grant date, subject to continuous service.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with the long-term performance of the company.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates